Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells

Sporadic, non-familial Parkinson's disease is characterized by a 15-30% reduction in complex I activity of the electron transport chain. A pharmacological model of reduced complex I activity was created by prolonged treatment of SH-SY5Y cells with low doses (5-20 nM) of rotenone, a selective inhibitor of complex I. Short-term (less than 2 week) exposure to rotenone did not influence calcium signaling, production of reactive oxygen species, or mitochondrial morphology. However, following 2 weeks of rotenone exposure, SH-SY5Y cells showed unusual calcium dynamics, specifically multiple calcium responses to carbachol, a muscarinic agonist. These secondary calcium responses were not seen in control SH-SY5Y cells and were dependent upon calcium influx. Mitochondrial membrane potential was also reduced in low dose rotenone-treated cells. These results demonstrate that a chronic, partial reduction in complex I activity, such as that seen in Parkinson's disease, can alter cell signaling events and perhaps increase the susceptibility of cells to calcium overload and subsequent cell death.

[1]  S. Dimauro,et al.  Mitochondria1 involvement in Parkinson's disease , 1993, Neurology.

[2]  C. Fall,et al.  Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. , 1997, Biochimica et biophysica acta.

[3]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[4]  R. Tsien,et al.  A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.

[5]  R. Swerdlow,et al.  Abnormal Mitochondrial Morphology in Sporadic Parkinson's and Alzheimer's Disease Cybrid Cell Lines , 2000, Experimental Neurology.

[6]  J. Schulz,et al.  Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra , 1997, Brain Research.

[7]  T. Pozzan,et al.  Ca2+ Homeostasis in the Agonist-sensitive Internal Store: Functional Interactions Between Mitochondria and the ER Measured In Situ in Intact Cells , 1998, The Journal of cell biology.

[8]  C. Moraes,et al.  Titrating the Effects of Mitochondrial Complex I Impairment in the Cell Physiology* , 1999, The Journal of Biological Chemistry.

[9]  Y. Imaizumi,et al.  Possible mechanism of the potent vasoconstrictor actions of ryanodine on femoral arteries from spontaneously hypertensive rats , 1996, British journal of pharmacology.

[10]  C. Fall,et al.  Visualization of cyclosporin A and Ca2+-sensitive cyclical mitochondrial depolarizations in cell culture. , 1999, Biochimica et biophysica acta.

[11]  D. Turnbull,et al.  Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease , 1991, Journal of the Neurological Sciences.

[12]  D. Bers,et al.  Oxygen-bridged Dinuclear Ruthenium Amine Complex Specifically Inhibits Ca2+ Uptake into Mitochondria in Vitroand in Situ in Single Cardiac Myocytes* , 1998, The Journal of Biological Chemistry.

[13]  C. Marsden,et al.  L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain , 1995, Movement disorders : official journal of the Movement Disorder Society.

[14]  K. Tipton,et al.  Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds , 1993, Journal of neurochemistry.

[15]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[16]  Samuel Thayer,et al.  Mitochondria buffer physiological calcium loads in cultured rat dorsal root ganglion neurons , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[17]  R. Helliwell,et al.  Modulation of Ca2+‐activated Cl− currents in rabbit portal vein smooth muscle by an inhibitor of mitochondrial Ca2+ uptake , 1997, The Journal of physiology.

[18]  M. Hoth,et al.  Mitochondrial Regulation of Store-operated Calcium Signaling in T Lymphocytes , 1997, The Journal of cell biology.

[19]  J. Parks,et al.  Mitochondrial DNA-depleted neuroblastoma (Rho‡) cells exhibit altered calcium signaling , 2000 .

[20]  T. Peng,et al.  Mitochondrial dysfunction in Parkinson's disease. , 1999, Biochemical Society symposium.

[21]  R. V. Sharma,et al.  Altered signal transduction in vascular smooth muscle cells of spontaneously hypertensive rats. , 1992, Hypertension.

[22]  D. Friel,et al.  An FCCP-sensitive Ca2+ store in bullfrog sympathetic neurons and its participation in stimulus-evoked changes in [Ca2+]i , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[23]  C. Arnoult,et al.  Pharmacological properties of the T-type Ca2+ current of mouse spermatogenic cells. , 1998, Molecular pharmacology.

[24]  R. Swerdlow,et al.  Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.

[25]  J. Cooper,et al.  Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease , 1998, Annals of neurology.

[26]  K. Jellinger,et al.  Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.

[27]  R. Benecke,et al.  Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. , 1993, Brain : a journal of neurology.

[28]  B. Freedman,et al.  Retrograde Ca2+ signaling in C2C12 skeletal myocytes in response to mitochondrial genetic and metabolic stress: a novel mode of inter‐organelle crosstalk , 1999, The EMBO journal.

[29]  H. Reichmann,et al.  Electron transport chain defects in Alzheimer's disease. , 1994, Neurology.

[30]  W. Fiers,et al.  Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene‐inductive effects of TNF. , 1993, The EMBO journal.

[31]  G. Steele,et al.  Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  W. Tatton,et al.  Mitochondria in neurodegenerative apoptosis: An opportunity for therapy? , 1998, Annals of neurology.

[33]  T. Pozzan,et al.  A Role for Calcium Influx in the Regulation of Mitochondrial Calcium in Endothelial Cells (*) , 1996, The Journal of Biological Chemistry.

[34]  M. Graeber,et al.  Regional heterogeneity of mtDNA heteroplasmy in parkinsonian brain. , 1996, Clinical neuropathology.

[35]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[36]  J. Langston,et al.  Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.

[37]  R. Swerdlow,et al.  Interaction Among Mitochondria, Mitogen‐Activated Protein Kinases, and Nuclear Factor‐κB in Cellular Models of Parkinson's Disease , 2000, Journal of neurochemistry.

[38]  J. Lunardi,et al.  The 49‐kDa subunit of NADH‐ubiquinone oxidoreductase (Complex I) is involved in the binding of piericidin and rotenone, two quinone‐related inhibitors , 1998, FEBS letters.

[39]  Robert E. Davis,et al.  Altered Calcium Homeostasis in Cells Transformed by Mitochondria from Individuals with Parkinson's Disease , 1997, Journal of neurochemistry.

[40]  T. Peng,et al.  Privileged access to mitochondria of calcium influx through N-methyl-D-aspartate receptors. , 1998, Molecular pharmacology.

[41]  T. Smith,et al.  J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. , 1991, Biochemistry.

[42]  P. Golstein Controlling Cell Death , 1997, Science.

[43]  C. Marsden,et al.  Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.

[44]  Isabel Llano,et al.  Intracellular calcium clearance in Purkinje cell somata from rat cerebellar slices , 1998, The Journal of physiology.

[45]  C. Marín,et al.  Mitochondria1 respiratory chain activity in skeletal muscle from patients with Parkinson's disease , 1993, Neurology.

[46]  J. Okun,et al.  Three Classes of Inhibitors Share a Common Binding Domain in Mitochondrial Complex I (NADH:Ubiquinone Oxidoreductase)* , 1999, The Journal of Biological Chemistry.

[47]  O. Blin,et al.  Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy , 1994, Journal of the Neurological Sciences.